|
3524
|
AKOS-022
|
VDAC1 inhibitor |
€120.00 |
|
4150
|
Birinapant
|
Bivalent Smac mimetic and potent antagonist for XIAP and cIAP1 inhibitor |
Inquire |
|
4010
|
BLK degrader compound 9
|
First potent and highly selective monomeric degrader of B-lymphoid tyrosine kinase (BLK) |
€180.00 |
|
4170
|
CB-5083
|
First-in-class potent, selective, and orally bioavailable inhibitor of p97 AAA ATPase |
€110.00 |
|
4169
|
CIQ
|
First NMDA NR2C/NR2D PAM |
€130.00 |
|
3580
|
DC-LC3in-D5
|
Autophagy inhibitor |
€140.00 |
|
4091
|
Deucravacitinib
|
Potent, highly selective, allosteric and orally bioavailable TYK2 inhibitor |
€150.00 |
|
4149
|
Everolimus
|
Selective and orally active mTOR1 inhibitor |
Inquire |
|
4018
|
FSEN1
|
Uncompetitive FSP1 inhibitor |
€120.00 |
|
4153
|
GS-9973
|
Selective Syk inhibitor |
Inquire |
|
4079
|
Insulin sensitizer C59
|
Insulin sensitizer by targeting Unc119b |
€110.00 |
|
3949
|
ISO-1
|
MIF inhibitor |
€120.00 |
|
4179
|
KU-0058948
|
Potent and specific PARP1 inhibitor |
€135.00 |
|
3927
|
NVP-DKY709
|
First-in-class selective CRBN glue degrader of IKZF2 |
€220.00 |
|
4152
|
Obatoclax
|
B-cell lymphoma-2 (BCL-2) inhibitor |
Inquire |
|
4167
|
RS504393
|
Selective CCR2 antagonist |
€110.00 |
|
4151
|
Ulixertinib hydrochloride
|
Potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases |
Inquire |
|
4166
|
Verubecestat
|
First-in-class, potent, orally bioavailable high-affinity BACE1 inhibitor |
€80.00 |